Living related partial liver transplantation in biliary atresia: 11 cases of experience.
Eleven children, 4 males and 7 females, with biliary atresia receiving living related liver graft were studied. The mean age was 1.8 years and the mean body weight was 10.3 kg. The donors were 4 fathers and 7 mothers. The graft was the lateral segment or left lobe. ABO blood group matching was compatible in 9 and incompatible in 2. All patients except one were crossmatch negative. Immunosuppression at induction was triple therapy (cyclosporine, azathioprine and steroid) or FK506 plus steroid. Acute rejection episodes were treated with pulse steroids. When the signs of rejection persisted despite steroid pulse therapy, 15-deoxyspergualin (DSG) was added. The survival rate of the patients was 73%. Three patients died of portal vein thrombosis, hepatic artery thrombosis and sepsis respectively. Other major complications included hyperbilirubinemia, bile duct stenosis, bile leakage and portal vein anastomosis narrowing. Complications of the donor were sepsis in one, and liver dysfunction in two. Although there are some complications related to graft size mismatch and operative procedure, living related partial liver transplantation is an effective therapy in countries where donor source is restricted.
Katoh
H
H
Second Department of Surgery, Tohoku University School of Medicine, Sendai, Japan.
Ohkohchi
N
N
Satomi
S
S
Shimaoka
S
S
Ohi
R
R
D000017:ABO Blood-Group System; D001656:Biliary Atresia / Q000601:surgery*; D002675:Child, Preschool; D005260:Female; D006084:Graft Rejection / Q000517:prevention & control; D006146:Guanidines / Q000627:therapeutic use; D006648:Histocompatibility; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007223:Infant; D007564:Japan / Q000453:epidemiology; D016031:Liver Transplantation; D019520:Living Donors; D008297:Male; D011183:Postoperative Complications / Q000453:epidemiology; D015996:Survival Rate; D013601:T-Lymphocytes / Q000276:immunology; D016559:Tacrolimus / Q000627:therapeutic use
D000017:ABO Blood-Group System; D006146:Guanidines; D007166:Immunosuppressive Agents; C037258:gusperimus; D016559:Tacrolimus